SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a
study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, September 14, 2020.

Conference Call/Webcast Details
The company will host a conference call and webcast with